NCT01497925View on ClinicalTrials.gov

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 6, 2011

Primary Completion Date

March 23, 2016

Study Completion Date

August 31, 2018

Conditions
Solid TumorsProstate Cancer
Interventions
DRUG

ADI-PEG 20

Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.

Trial Locations (1)

95817

University of California at Davis, Sacramento

Sponsors

Lead Sponsor

Polaris Group
All Listed Sponsors
lead

Polaris Group

INDUSTRY